The U.S Center for Disease Control and Prevention reported that  “In early October, 3.4 million vaccines against influenza A will be distributed most of them in a nasal spray.

Jay Butler, medical advisor to the CDC said in a conference call that “The vaccine will become available on the first week of October, we will distribute an initial shipment of at least 3.4 million doses in around 90 thousand approved centers nationwide.

And that “Our data suggest that virtually all of them will be administered by nasal spray, although we may also have some doses available as an injection.

The CDC received data from the four manufacturers who on Tuesday obtained a license from the Food and Drug Administration to begin distributing the vaccine.

The patented spray, named FluMist, is approved only for use in healthy individuals aged 2 to 49 years. The population considered “at risk” is excluded by the Department of Health in the United States such as infants or those over 50 who have  breathing problems.

Kathleen Sebelius, Secretary of Health, reported that “The first doses will be reserved for those who are part of the risk population, such as pregnant women, those under 24 years, people who care for infants and young workers health sector “.

And that “these groups total about 160 million people in the country, which would exhaust most of the vaccine supply bought by the U.S. government.”

From October the Control Center, according to information from Butler, “expects to ship, some 20 million doses a week,” clarifying that “to have delivered in December and 195 million acquired by the Health Department” said Butler.

The vaccine was developed with weakened live virus AH1N1, while the injection is based on dead virus.